Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil by Sue Ann Costa Clemens, MD, PhD, Sagida Bibi, PhD, Natalie G. Marchevsky, MSc, Parvinder K. Aley, PhD, Federica Cappuccini, PhD, Sophie A. Davies, BSc, Isabela Gonzalez, PhD, Sarah C. Kelly, MSc, Yama F. Mujadidi, MSc, Eveline Pipolo Milan, MD, PhD, Alexandre V. Schwarzbold, PhD, Eduardo Sprinz, MD, DSc, Merryn Voysey, DPhil, Lily Y. Weckx, MD, PhD, Daniel Wright, DPhil, Himanshu Bansal, MS, Maria A.S. Bergagård, MSc, Abby J. Isaacs, MS, Elizabeth J. Kelly, PhD, Dongmei Lan, MS, Shethah Morgan, PhD, Nirmal Kumar Shankar, BAMS, Kathryn Shoemaker, MS, Tonya L. Villafana, PhD, Teresa Lambe, PhD, Justin A. Green, MD, PhD, Andrew J. Pollard, FMedSci

Get full text